Overview

Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A

Status:
Withdrawn
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to compare the pharmacokinetic parameters of ReFacto and Advate, using the chromogenetic substrate assay to measure plasma Factor VIII activity in plasma.
Phase:
Phase 4
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Factor VIII